8-K: CERo Therapeutics Reports Positive Phase 1 AML Trial Update

CERo Therapeutics announced encouraging safety data and a significant platelet transfusion-free interval in its Phase 1 CertainT-1 trial for AML, leading to an expansion of the study to include MDS and MF patients.

Summary

• A clinical update on the Phase 1 CertainT-1 trial for Acute Myeloid Leukemia (AML) was provided.
• Robust cell expansion was observed with no Cytokine Release Syndrome (CRS), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), or treatment-related adverse events reported to date in all 4 patients.
• Repeat dosing of CER-1236 is feasible without lymphodepletion, showing several-fold cell expansion after reinfusion.
• A 74-year-old patient (Patient 2) with Myelodysplastic Syndrome (MDS) progressing to AML, who was previously transfusion-dependent, experienced a 61-day platelet transfusion-free interval after CER-1236 treatment.
• The 61-day interval exceeded the commonly used 8-week threshold for durable platelet transfusion independence.
• The trial protocol was amended in December 2025 to include additional indications: advanced MDS (Transfusion-Dependent and High-Risk) and Myelofibrosis (MF) (Post-JAK Failure).
• The company plans to use this update in meetings with investors and analysts.
• An analyst call was scheduled for January 7, 2026, at 5:00 PM ET to discuss progress and the go-forward strategy.

Sentiment

Score: 8

Explanation: The clinical update presents strong positive safety data (no CRS, ICANS, or treatment-related AEs) and a promising efficacy signal (61-day platelet transfusion-free interval) in a difficult-to-treat patient population. The expansion of the trial to include additional indications (MDS, MF) further underscores the positive outlook and potential broader applicability of CER-1236. While early-stage, these are significant milestones.

Positives

• Robust cell expansion observed in all 4 patients treated with CER-1236.
• No Cytokine Release Syndrome (CRS) reported to date in all 4 patients.
• No Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) reported to date in all 4 patients.
• No treatment-related adverse events reported to date.
• Repeat dosing of CER-1236 is feasible without lymphodepletion.
• A 61-day platelet transfusion-free interval was observed in a 74-year-old MDS/AML patient, exceeding the 8-week benchmark for durable platelet transfusion independence.
• The clinical course of Patient 2 is encouraging and supports continued evaluation of CER-1236 in diseases of the bone marrow.
• The trial was expanded to include advanced MDS and myelofibrosis, indicating potential broader applicability of CER-1236.

Negatives

• Transfusion independence in Patient 2 ended following a subsequent round of lymphodepleting chemotherapy plus CER-1236 treatment.
• The VERONA trial, an industry benchmark, did not demonstrate an overall survival benefit for venetoclax added to HMAs in MDS, highlighting the significant unmet need and challenges in this disease area.

Risks

• The business is subject to a number of risks, including those set forth in the most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
• Forward-looking statements are subject to risks and uncertainties, and actual events and circumstances are difficult or impossible to predict and will differ from assumptions.
• Product candidates are under preclinical or clinical study and have not yet been approved for marketing by the U.S. Food and Drug Administration; no representation is made as to their safety or effectiveness for the uses for which they are being studied.
• The transfer of securities may be subject to conditions, and investors might be required to bear the final risk of their investment for an indefinite period of time.

Future Outlook

The company expects to continue dose escalation in the CertainT-1 trial, both in terms of volume and frequency. Management looks forward to sharing additional details and communicating with regulatory authorities for continued development. The trial has been expanded to include advanced MDS and myelofibrosis patients, indicating a broader development strategy for CER-1236. The company also plans to evaluate submission of data for scientific publication.

Management Comments

• Robert Sikorski, M.D., Ph.D., Chief Scientific Officer: "The patient's clinical course, including a platelet transfusion-free interval despite having advanced MDS/AML, is encouraging and supports continued evaluation of CER-1236 in diseases of the bone marrow. We have amended the CertainT-1 trial to expand the focus to include MDS and MF patients going forward."
• Chris Ehrlich, CEO: "The evolution of this trial to MDS and MF is an important milestone as we continue to dose escalate, both in terms of volume and frequency. We are looking forward to sharing additional details in our call this afternoon, and to communicating with all stakeholders — including regulatory authorities — toward the continuing of its development. We also remain grateful to our trial patients for their participation as well as the loyal and long-time shareholders who continue to ensure that the Company is able to conduct this work. We remain focused on the careful and deliberate conduct of the dose-escalation phase and the systematic collection of safety data as the trial proceeds and we seek to expand its initial focus."

Industry Context

The filing highlights the significant unmet need in higher-risk MDS, where HMAs remain the only approved disease-modifying therapies and the VERONA trial did not show an overall survival benefit for venetoclax added to HMAs. CERo's CER-T cell approach is presented as a novel cellular immunotherapy platform designed to offer advantages over currently approved CAR-T therapies by integrating both innate and adaptive immunity, potentially extending cellular immunotherapy to both hematologic malignancies and solid tumors. The observed transfusion independence in Patient 2 represents an early, clinically meaningful signal in MDS, a challenging area with limited effective treatments.

Comparison to Industry Standards

• The 61-day platelet transfusion-free interval observed in Patient 2 exceeded the commonly used 8-week (approximately 56-day) threshold for durable platelet transfusion independence cited in clinical studies.
• CERo believes its differentiated targeting properties of CER-T cells may offer advantages compared with currently approved CAR-T therapies by employing phagocytic activity to destroy cancer cells.
• The VERONA trial, which investigated venetoclax added to HMAs for MDS, did not demonstrate an overall survival benefit, indicating a high unmet need that CERo's CER-1236 could potentially address with its novel mechanism.

Stakeholder Impact

• Shareholders: Positive clinical data and trial expansion could increase investor confidence and potentially lead to share price appreciation. The company is actively engaging with investors and analysts.
• Patients: The observed safety profile and early efficacy signal (platelet transfusion-free interval) offer hope for new treatment options for patients with advanced AML, MDS, and potentially MF, especially those who have failed previous therapies.
• Employees: Continued progress in clinical trials supports the company's mission and ongoing research and development efforts, potentially boosting morale and stability.
• Regulatory Authorities: The company plans to communicate with regulatory authorities regarding the continued development of CER-1236, indicating ongoing engagement and adherence to regulatory pathways.

Next Steps

• Continue dose escalation in the CertainT-1 trial, both in terms of volume and frequency.
• Share additional details in future communications.
• Communicate with regulatory authorities toward the continuing development of CER-1236.
• Systematic collection of safety data as the trial proceeds.
• Evaluate submission of data for scientific publication.
• Engage in exploratory discussions with potential partners at ASH.

Key Dates

Recommendation

The clinical update for CER-1236 demonstrates a robust safety profile with no CRS, ICANS, or treatment-related adverse events, which is critical for cellular immunotherapies. The observed 61-day platelet transfusion-free interval in a heavily pre-treated MDS/AML patient is a clinically meaningful early efficacy signal, exceeding industry benchmarks. The strategic decision to expand the Phase 1 trial to include advanced MDS and myelofibrosis indicates management's confidence in the drug's broader potential and addresses significant unmet medical needs. These factors, combined with the early stage of development and potential for future catalysts, suggest a strong upside for investors willing to take on clinical trial risk.

Keywords

CERo Therapeutics, CER-1236, AML, MDS, Myelofibrosis, CertainT-1 trial, Phase 1, cellular immunotherapy, CAR-T, Chimeric Engulfment Receptor T cells, CER-T, clinical trial, hematologic malignancies, oncology, biotechnology, drug development, TIM-4